Healthcare
Live Price
Offline$27.44
+1.97% today
1Y Change
-33.89%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ultragenyx Pharmaceutical Inc. (RARE) is a Healthcare stock with a market cap of $2.44B and listed on NASDAQ. The stock last traded around $27.44 and down 33.9% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +20.1%, EPS growth of +7.3%, a dividend yield of 0.0%. What stands out right now is revenue +20.1%, EPS +7.3%, free cash flow -11.9% with operating margin -79.6% and ROIC -43.6%. Valuation is more restrained than many high-expectation growth names at price/sales 3.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RARE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RARE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RARE Max Drawdown
-55.36%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RARE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$351.4M
-3.3% YoY
FY Net Income
-$454.0M
+35.8% YoY
Free Cash Flow
-$411.8M
+21.8% YoY
Revenue Growth
+20.1%
EPS Growth
+7.3%
Gross Margin
83.8%
Net Margin
-85.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 673M | 560M | 434M | 363M | 351M |
| Gross Profit | 564M | 484M | 389M | 335M | 335M |
| Operating Income | -535M | -536M | -569M | -649M | -382M |
| EBITDA | -500M | -469M | -516M | -640M | -410M |
| Net Income | -575M | -569M | -607M | -707M | -454M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 434M | 174M | 214M | 133M | 308M |
| Total Assets | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Total Liabilities | 1.6B | 1.2B | 1.2B | 1.2B | 600M |
| Shareholder Equity | -80M | 255M | 275M | 352M | 923M |
| Total Debt | 1.3B | 40M | 43M | 32M | 42M |
| Net Debt | 842M | -133M | -170M | -101M | -266M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
339M
+11.0% YoY
Capital Expenditures
73M
+50.0% YoY
Free Cash Flow
412M
+21.8% YoY
Key ratios
Gross Margin
83.8%
Operating Margin
-79.6%
Net Margin
-85.5%
ROE
-1024.4%
Debt / Equity
-15.95x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.